Mesco Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 30.00 Cr
as on 04-10-2024
- Paid Up Capital ₹ 19.74 Cr
as on 04-10-2024
- Company Age 38 Year, 4 Months
- Last Filing with ROC 31 Mar 2021
- Satisfied Charges ₹ 10.00 Cr
as on 04-10-2024
- Revenue %
(FY 2021)
- Profit 95.93%
(FY 2021)
- Ebitda 96.07%
(FY 2021)
- Net Worth -0.04%
(FY 2021)
- Total Assets -16.63%
(FY 2021)
About Mesco Pharmaceuticals
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 500274.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 30.00 Cr and a paid-up capital of Rs 19.74 Cr.
The company has closed loans amounting to ₹10.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Mesco Pharmaceuticals Limited India are Santosh Jha as Cfo, Nurani Parameswaran as Company Secretary, and Dhruv Singh as Ceo. Dushyant Singh, Hawa Chahar, and Dhruv Singh serve as directors at the Company.
- CIN/LLPIN
L24111UR1986PLC015895
- Company No.
015895
- Stock Symbol
BSE : 500274
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
12 Aug 1986
- Date of AGM
29 Sep 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Listed
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Nainital, Uttarakhand, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Mesco Pharmaceuticals?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santosh Jha  | CFO | 25-Feb-2015 | Current |
| Nurani Parameswaran | Company Secretary | 25-Mar-2019 | Current |
| Dhruv Singh | CEO | 31-Jul-2020 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Dushyant Singh | Director | 12-Aug-1986 | Current |
| Hawa Chahar | Director | 21-Jun-2019 | Current |
| Dhruv Singh | Director | 31-Jul-2020 | Current |
Financial Performance and Corporate Structure Insights of Mesco Pharmaceuticals.
Mesco Pharmaceuticals Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 95.93% increase in profit. The company's net worth dipped by a decrease of 0.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mesco Pharmaceuticals?
In 2020, Mesco Pharmaceuticals had a promoter holding of 39.30% and a public holding of 60.70%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_LIMITED.webp)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Industrial Finance Corporation Of India Creation Date: 16 Mar 1995 | ₹10.00 Cr | Satisfied |
How Many Employees Work at Mesco Pharmaceuticals?
Unlock and access historical data on people associated with Mesco Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mesco Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mesco Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
